Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (September 2005)
34 slides from Anesiva's merger presentation, Sep 26, 2005
Slide 1: Corgentech and AlgoRx Announce Merger Agreement
Corgentech and AlgoRx Announce Merger Agreement September 26, 2005
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “pla
Slide 3: Forward Looking Statements (2)
FORWARD LOOKING STATEMENTS (2) Additional Information and Where to Find It Corgentech Inc. intends to file a registration statement on Form S-4, and Corgentech and AlgoRx Pharmaceuticals, Inc. intend to file a related joint proxy statement/prospectus, in connection with the merger transaction involv
Slide 4: Creating a Late-Stage Company
CREATING LATE-STAGE COMPANY Multiple late-stage product development programs focused on significant clinical problems – Pain management – Inflammatory diseases Brings together development and commercial expertise in critical areas – Marketing, commercialization, regulatory affairs and clinical trial
Slide 5: Agenda
AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense
Slide 6: Terms of Merger Agreement
TERMS OF MERGER AGREEMENT Stock Transaction – As of the date of closing of the merger agreement, Corgentech would issue sufficient shares such that AlgoRx shareholders would receive, in a tax-free exchange, 62% of the combined company and Corgentech shareholders would own 38% of the combined company
Slide 7: Agenda
AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense
Slide 8: Product Pipeline
PRODUCT PIPELINE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ALGRX 3268 Pre-procedural analgesia ALGRX 4975 Post-surgical pain Morton’s neuroma Tendonitis NF-KB Decoy Atopic dermatitis (eczema) ALGRX 1207 Cutaneous neuropathic pain
Slide 9: ALGRX 3268 - Topical Local Anesthesia
ALGRX 3268- TOPICAL LOCAL ANESTHESIA Indication – Reduction of pain associated with needlesticks for venipunctures and intravenous line placements Phase 3 trial underway – Clinical data expected in second half of 2005 Key desirable product attributes – Sterile, pre-filled, needle-free disposable del
Slide 10: ALGRX 3268: Reduction in Pain from Venipuncture
ALGRX 3268 Reduction in Pain from Venipuncture after Administration EMLA Package Insert for EMLA VAS, mm 10 0 -10 -20 -30 Time after administration, minutes ALGRX 3268 VAS, mm 10 0 -10 -20 -30 Time after administration, minutes ALGRX 3268 has an onset within one minute, whereas EMLA is labeled for a
Slide 11: ALGRX 3268 Development
ALGRX 3268 DEVELOPMENT Protocol Age Group Phase Total Patients Primary Endpoint Status Primary Endpoint Antecubital Fossa Adults 1 272 Safety and Efficacy Achieved Primary Endpoint Back of Hand Adults 1 183 Safety and Efficacy Achieved Evaluate Circulating Primary Endpoint Pharmacokinetics Adults 1
Slide 12: ALGRX 4975 - VR1 Anesthetic
ALGRX 4975 – VR1 ANESTHETIC Activates the VR1 channel; expressed by pain receptor C-fibers Capsaicin Overview Administered locally at the site of pain Single administration may provide analgesia for weeks to months Non-opioid based Only reduces long-term noxious pain associated with C-neurons Does n
Slide 13: ALGRX 4975 Development
ALGRX 4975 DEVELOPMENT Protocol Phase Total Patients Primary Endpoint Status Postsurgical Pain Bunion Removal Surgery 2 40 Time to Rescue Medication Primary Endpoint Achieved Bunion Removal Surgery 2 182 Magnitude of Pain Relief Primary Endpoint Achieved Hernia Repair 2 48 Magnitude and Duration of
Slide 14: Eczema: Large Unmet Need
ECZEMA: LARGE UNMET NEED Unmet medical need – Existing therapies are not satisfactory (steroids and calcineurin inhibitors) – Safety issues with long-term application of steroids, especially in children, and black box warning for cancer risk on on calcineurin inhibitors Strong preclinical data with
Slide 15: NF-kB Decoy for Eczema
NF-KB DECOY FOR ECZEMA Two Phase 1/2 trials underway Clinical data expected in 1Q/06 Adults with mild-moderate eczema Endpoints – Safety, tolerability and PK – Multiple endpoints to assess preliminary efficacy Physician and patient assessments of target area (signs and symptoms) US Trial (75 patient
Slide 16: ALGRX 1207
ALGRX 1207 IND-enabling studies underway New chemical class of local anesthetic for topical analgesia Deep, rapid penetration of the skin and long duration of action Addresses a wide variety of procedures including: – Neuropathic pain – Dermatological surgery – Surgical incisions
Slide 17: ALGRX 1207
ALGRX 1207 New local anesthetic allowing rapid and complete topical anesthesia without exotic delivery Percent complete anesthesia 100 80 60 40 20 0 -120 -110 -100 -90 Time, minutes Percent complete anesthesia 100 80 60 40 20 0 -120 -60 0 60 120 180 240 300 360 420 Time, minutes Lidocaine ALGRX 1207
Slide 18: Agenda
AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense
Slide 19: Prevalence of Pain in Seven Major Countries
PREVALANCE OF PAIN IN SEVEN MAJOR COUNTRIES PATIENT NUMBERS (in thousands) Prevalence of post-operative pain 75,068 Prevalence of back pain 208,996 Prevalence of HIV and AIDS pain 847 Prevalence of diabetic neuropathy pain 13,243 Prevalence of osteoarthritic pain 46,610 Above indications are all tar
Slide 20: 3268: Topical Local Anesthesia Market Dynamics
3268: TOPICAL LOCAL ANESTHESIA MARKET DYNAMICS Strong focus of pain management including treatment protocols and guidelines Increase in dedicated pediatric hospitals and specialized pediatric departments in larger general hospitals Continuing pressure on cost reduction and patient through-put in hos
Slide 21: 3268: Needlestick/Venipuncture Marketplace in the U.S.
3268: NEEDLESTICK/VENIPUNCTURE MARKETPLACE IN THE U.S. 42M Pediatric in-hospital 315M Adult in-hospital 40M Hemodialysis visits 54K Pediatric physician offices 11K Outpatient care centers1 1.3K Blood donation centers1 At home self-administration market 1. 2001 US census
Slide 22: 3268: TLAs in Pediatric Hospital Settings
3268: TLAs IN PEDIATRIC HOSPITAL SETTINGS Relevant Pediatric Procedures Surgery/ IV Insertions 12% Spinal Tap/ LPs 12% Chemotherapy 1% Blood Draws 48% IV Insertions 27% 18 million procedures* Treated Relevant Procedures Spinal Tap/ LPs 11% Chemotherapy 3% Surgery/ IV Insertions 19% IV Insertions 35%
Slide 23: 3268: Current Clinical Practice of TLAs in Hospital Setting
3268: CURRENT CLINICAL PRACTICE OF TLAs IN HOSPITAL SETTING Many hospitals offer TLA agents as an option to reduce needlestick pain – Existence of established protocols for TLA use is mixed – Nurses rather than physicians usually decision maker Some ERs apply TLAs, however use is often impractical d
Slide 24: 3268: Phased Marketing Approach
3268: PHASED MARKETING APPROACH Physican Offices, Labs, Blood donation centers Hemodialysis Centers In-hospital Adult (ER) In-hospital Pediatric 18M
Slide 25: 4975: Post-Operative Pain Market
4975: POST-OPERATIVE PAIN MARKET US post-operative pain market: $1.7 billion Virtually all patients experience some level of pain post operatively – 50% indicate lack of adequate pain control – Patients’ post-surgical pain experiences between 1993 and 1999 have not improved – Europe also under treat
Slide 26: 4975: Potential Targets - High Volume Surgical Procedures
4975: POTENTIAL TARGETS—HIGH VOLUME SURGICAL PROCEDURES Procedure Volume Caesarean Section 1,163,893 Hysterectomy (all) 1,042,715 Episiotomy 417,699 Arthroplasty (knee) 399,139 Hip Replacement, 343,554 total/partial CABG 316,471 Colorectal resection 280,969
Slide 27: Current Post-Op Pain Medications vs. ALGRX 4975
CURRENT POST-OP PAIN MEDICATIONS VS. ALGRX 4975 Epidurals – Use declining significantly due to contra-indication in combination use with anticoagulants Opioids – Nausea, vomiting, respiratory depression and constipation – Sedation may limit the ability of the patient to ambulate and prolong time to
Slide 28: NF-kB Decoy: Eczema Market
NF-KB DECOY: ECZEMA MARKET Eczema market is comprised of mild, moderate and severe patient segments within the pediatric and adult patient populations Patient Population Segmented by Mild, Moderate and Severe (US, EU, Japan) Severe 10% 15.6M 5.2M 31.1M Moderate 30% Mild 60% Sources: 1. International
Slide 29: NF-kB Decoy: Retail Rx Sales (U.S.)
NF-KB DECOY: RETAIL Rx SALES (U.S.) Total Dollars (millions) $900 $800 $700 $600 $500 $400 $300 $200 $100 $0 1999 2000 2001 2002 2003 2004 Corticosteroids Protopic Elidel Source: IMS Health, 2004
Slide 30: 1207: Target Market
1207: TARGET MARKET Deep, rapid penetration of the skin Long duration of action Addresses neuropathic pain market Non-exotic delivery Lidoderm® (Endo Pharmaceuticals) Postherpetic Neuralgia Indication ($ in millions) $45 $107 $215 $300 $400 2001 2002 2003 2004E 2005E (IMS) (IMS) (IMS) (Endo) (Endo)
Slide 31: Agenda
AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense
Slide 32: Deal Timeline
DEAL TIMELINE Merger requires stockholder approval – Both boards have approved the merger Merger documents to be filed in coming weeks – S-4 and related joint Proxy Statement Shareholder vote expected to occur in late 2005 / early 2006
Slide 33: Agenda
AGENDA Terms of merger agreement Product pipeline of combined company Commercial potential of products Deal timeline Why this merger makes sense
Slide 34: Why This Merger Makes Sense
WHY THIS MERGER MAKES SENSE Multiple late-stage product development programs focused on significant clinical problems – Pain management – Inflammatory diseases Brings together development and commercial expertise in critical areas – Marketing, commercialization, regulatory affairs and clinical trial
Algorx Pharmaceuticals — Merger or Acquisition (September 2005) on 6ix